Section 5 of 6
Economic information and modeling report
21 evidence topics · 12 sources
Modeling overview
Summary
No published cost-effectiveness analysis, budget impact model, or announced price exists for VK2735; the evaluations below describe the incretin-based anti-obesity medications it would join. The ICER final evidence report of December 2025 modeled injectable semaglutide, oral semaglutide (at an assumed price equal to that of injectable semaglutide), and tirzepatide, each added to lifestyle modification, over a lifetime horizon from the health care sector perspective. At annual net prices of $6,829 for semaglutide and $7,973 for tirzepatide, the incremental cost-effectiveness ratios versus lifestyle modification were $57,779 per QALY gained for tirzepatide, $66,355 for injectable semaglutide, and $75,456 for oral semaglutide, and no discount was needed to reach the health benefit price benchmark of any of the three. ICER estimated about 92 million eligible U.S. adults and found that fewer than 1% could be treated within five years before its $880 million annual budget impact threshold was crossed, including at a Medicare price of $245 per month, and issued an access and affordability alert.
Other U.S. analyses reached different conclusions depending on the drug price and the perspective. The ICER 2022 assessment (semaglutide $237,000 per QALY gained) and a 2025 lifetime microsimulation (tirzepatide $197,023 and semaglutide $467,676 per QALY gained) found the GLP-1-based drugs not cost-effective at the net prices then assumed. A 30-year U.S. third-party payer model found semaglutide 2.4 mg cost-effective against all comparators at $150,000 per QALY gained, and a societal-perspective model based on SURMOUNT-5 found tirzepatide less costly and more effective than semaglutide. For Medicare, CBO estimated that authorizing coverage of anti-obesity medications would increase net federal spending by about $35 billion from 2026 to 2034, with a direct federal cost of about $5,600 per user in 2026, and a separate analysis estimated $3.1 billion to $6.1 billion in added annual Part D costs at 5% to 10% uptake among newly eligible beneficiaries. The CMS Medicare GLP-1 Bridge demonstration provides certain GLP-1 drugs to eligible Part D beneficiaries for a $50 copay from July 1, 2026, to December 31, 2027. In 2025, 19% of firms with 200 or more workers, and 43% of firms with 5,000 or more workers, covered GLP-1 agonists for weight loss.
Product-specific economic evaluation of VK2735
No evidence found.
ICER model: structure, perspective, time horizon, and discounting
ICER base case: incremental cost-effectiveness ratios versus lifestyle modification
ICER health benefit price benchmarks based on QALYs gained
ICER appraisal committee votes on long-term value for money
ICER potential budget impact: eligible population, uptake, and time horizon
ICER potential budget impact: annual budget impact per patient treated
ICER policy findings on utilization, persistence, and pricing of current and pipeline products
Prior ICER assessment: incremental cost-effectiveness ratios at earlier net prices
| Treatment versus lifestyle modification | Cost per QALY gained, $ | Cost per evLY gained, $ |
|---|---|---|
| Semaglutide | “237,000”View highlighted excerpt for this quote | “234,000”View highlighted excerpt for this quote |
| Liraglutide | “483,000”View highlighted excerpt for this quote | “473,000”View highlighted excerpt for this quote |
| Phentermine/topiramate | “8,000”View highlighted excerpt for this quote | “7,000”View highlighted excerpt for this quote |
| Bupropion/naltrexone | “123,000”View highlighted excerpt for this quote | “121,000”View highlighted excerpt for this quote |
“At the current price net of rebates, the incremental cost-effectiveness ratio for semaglutide and liraglutide exceeded the commonly accepted thresholds (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For semaglutide, the panel members voted that its long-term value for money at its current pricing is low (11/15 votes) or intermediate (4/15 votes).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lifetime microsimulation of four anti-obesity medications in U.S. adults
“Data were included from the 2017-2020 National Health and Nutrition Examination Survey of 4823 individuals (representing 126 million eligible US adults) aged 20 to 79 years who would meet clinical trial inclusion criteria for antiobesity medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the largest incremental QALY gains of 0.35 for tirzepatide and 0.25 for semaglutide among all antiobesity medications, the incremental cost-effectiveness ratios were $197 023/QALY and 467 676/QALY, respectively. To reach the $100 000/QALY threshold, their prices would require additional discounts by 30.5% for tirzepatide and 81.9% for semaglutide from their current net prices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Naltrexone-bupropion was cost saving due to its lower cost and had an 89.1% probability of being cost-effective at $100 000/QALY, whereas phentermine-topiramate had a 23.5% probability of being cost-effective at $100 000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide 2.4 mg versus diet and exercise and other anti-obesity medications: U.S. third-party payer model
“A cohort Markov model was constructed to compare semaglutide 2.4 mg with the following comparators: no treatment, diet and exercise (D&E), and 3 branded AOMs (liraglutide 3 mg, phentermine-topiramate, and naltrexone-bupropion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base-case analysis, treatment with semaglutide 2.4 mg was estimated to improve QALYs by 0.138 to 0.925 and incur higher costs by $3,254 to $25,086 over the 30-year time horizon vs comparators. Semaglutide 2.4 mg is cost-effective against all comparators at the prespecified WTP threshold, with the incremental cost per QALY gained ranging from $23,556 to $144,296 per QALY gained.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the sensitivity analysis, extended maximum treatment duration, types of subsequent treatment following therapy discontinuation, and weight-rebound rates were identified as key drivers for model results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide versus semaglutide from a head-to-head trial: U.S. societal perspective model
“This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide and tirzepatide in knee osteoarthritis with obesity
“Tirzepatide provided greater health benefits at lower costs than semaglutide and yielded a $57,400/QALY ICER vs. diet and exercise.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tirzepatide’s ICER was most sensitive to changes in medication costs, treatment efficacy, and cohort baseline BMI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries eligible for anti-obesity medication coverage through an additional indication
“The study sample included 3,277 adults with overweight or obesity on Medicare with prescription coverage without Medigap, representing 25,397,971 adults. Among this population, 34.2% (95% CI, 32.0–36.5%) or 8.7 million people were eligible for AOMs through Medicare pre-March 2024. Post-March 2024, 46.4% (95% CI, 43.9–48.8) or 11.8 million people were eligible for AOMs through Medicare.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Semaglutide for secondary prevention of cardiovascular disease: lifetime cost-effectiveness and spending
“The model incorporated annual semaglutide cost of $8604 (2023 US price net of rebates and discounts) and adopted a health-system perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adding semaglutide to usual care in the estimated 4 million US adults without diabetes eligible for secondary prevention of CVD is projected to avert 358 400 MACE at a cost of $148 100 per QALY gained (95% uncertainty interval, $127 100-$173 400).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with semaglutide was projected to increase annual health care spending by $23 billion. Semaglutide would be cost-effective at a threshold of $120 000 per QALY gained if the annual cost were lowered an additional 18% to $7055.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Federal budgetary effects of authorizing Medicare coverage of anti-obesity medications
Estimated Medicare Part D spending if anti-obesity medications were covered
“Assuming that anti-obesity drugs were covered in 2025 and that 5 percent or 10 percent of newly eligible patients were prescribed one, annual Part D costs were estimated to increase by $3.1 billion or $6.1 billion, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Longer-term estimates come with significant uncertainty about utilization and price changes, but these results are consistent with this policy change likely increasing Medicare costs by the low to middle tens of billions of dollars over ten years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare GLP-1 Bridge demonstration: period and beneficiary copay
Employer coverage of GLP-1 agonists for weight loss
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.